Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,383.00GBp
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
5,383.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,014,631
52-wk High
5,585.07
52-wk Low
4,260.00

Select another date:

Tue, Jun 12 2018

Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

June 12 Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease.

AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca's first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

AstraZeneca cancer drug hits second goal by extending survival

LONDON AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

AstraZeneca cancer drug hits second goal by extending survival

LONDON, May 25 AstraZeneca's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch.

AstraZeneca potassium drug finally approved, threatening Vifor

LONDON The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

AstraZeneca potassium drug finally approved, threatening Vifor

LONDON, May 21 The decision by U.S. regulators to finally approve AstraZeneca's much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products.

AstraZeneca pay report rejected by 35 percent of shareholders

LONDON More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme.

AstraZeneca pay report rejected by 35 pct of shareholders

LONDON, May 18 More than a third of AstraZeneca shareholders staged a revolt over bonuses at the pharmaceutical company on Friday, following concerns about levels of disclosures and outcomes under the company's incentive scheme.

AstraZeneca insists future is bright after big Crestor sales hit

LONDON AstraZeneca's first-quarter profit was hit by generic competition to cholesterol fighter Crestor and higher costs, but the drugmaker expects a better second half and said it remained on track for a promised return to sales growth in 2018.

UPDATE 2-AstraZeneca insists future is bright after big Crestor sales hit

* Q1 sales and earnings miss forecasts as Crestor, costs weigh

Select another date: